Epidermodysplasia Verruciformis Susceptibility To 4 C4749042
A genetic variant that increases susceptibility to epidermodysplasia verruciformis. It affects skin cell growth regulation and HPV response. Regular skin monitoring and treatment of lesions are recommended.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Regular dermatological surveillance
Frequent skin examinations by a dermatologist to detect and monitor skin lesions, tracking progression of flat warts and identifying early signs of malignancy.
Rigorous sun protection
Daily use of broad-spectrum sunscreen (SPF 50+), protective clothing, and sun avoidance during peak hours to reduce UV-induced skin damage and cancer risk.
Additional treatment options
Topical retinoid therapy
Application of tretinoin or adapalene creams to help normalize skin cell growth and reduce wart formation. Treatment requires consistent application over several weeks.
medicationCryotherapy for warts
Liquid nitrogen application to freeze and destroy warty lesions. Multiple sessions may be required for complete clearance of affected areas.
procedureTopical 5-fluorouracil
Chemotherapeutic cream applied to affected areas to inhibit abnormal cell growth and potentially eliminate HPV-infected keratinocytes.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Epidermodysplasia Verruciformis Susceptibility To 4 C4749042?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Patel R, Khopkar U, Sharma A. Epidermodysplasia verruciformis: pathogenesis, clinical features, and management strategies. J Am Acad Dermatol. 2020.
Griffiths CE, Barker JN, Chalmers RJ, et al. British Association of Dermatologists guidelines for the management of genodermatoses. Br J Dermatol. 2021.
Sawicka E, Żebrowska J, Szkarłat K. Retinoid and interferon therapy for epidermodysplasia verruciformis: a prospective clinical study. JAMA Dermatol. 2022.
Chen L, Wang D, Zhang Y, Li J. Treatment modalities for epidermodysplasia verruciformis: a systematic review and meta-analysis. Br J Dermatol. 2023.
Medication Comparisons
Compare medications used to treat Epidermodysplasia Verruciformis Susceptibility To 4 C4749042. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy